SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V}
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BRAVEHEART who wrote (343)4/2/2000 12:41:00 PM
From: dalroi  Read Replies (2) of 423
 
from the lone star growth fund

seems intresting

UroCor (UCOR) is not a "sexy company." It provides diagnostic and
therapeutic services for urologists. UroCor shares trade at a price to
book ratio of one and have no debt. Last month, the FDA approved two
drug-related products that address prostate and bladder problems.
UroCor's diagnostic services are administered to roughly one third of
the nations urologist. "We believe revenues are going to increase 20-40
percent in the next year and earnings should be pushed much higher."

Stefaan
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News